On this page
Niemann-Pick disease type A
This severe condition typically presents in infancy and affects multiple organs, leading to significant developmental challenges and reduced life expectancy. It is caused by genetic changes inherited from both parents.
Available at Jeen Health
Clinical tests that include this
Overview
Niemann-Pick disease type A (NPD-A) is a very rare, inherited metabolic condition that affects the body's ability to break down certain fats, specifically sphingomyelin. In NPD-A, a specific enzyme, acid sphingomyelinase (ASM), is severely deficient or completely absent. This enzyme is crucial for breaking down sphingomyelin within lysosomes, which are like the recycling centres of cells [PMID:30138920]. Without enough functional ASM, sphingomyelin builds up to toxic levels inside cells, particularly in organs such as the liver, spleen, lungs, bone marrow, and brain.
The accumulation of sphingomyelin leads to widespread cellular damage and dysfunction. NPD-A is considered the most severe form within the Niemann-Pick disease spectrum, primarily distinguished by its early onset and significant neurological involvement. It is an autosomal recessive condition, meaning an individual must inherit a faulty gene from each parent to develop the disorder.
Symptoms & clinical features
Symptoms of Niemann-Pick disease type A typically begin in early infancy, often within the first few months of life. Affected infants may fail to thrive, meaning they do not gain weight or grow as expected. A key physical sign is an enlarged liver and spleen (hepatosplenomegaly), which can become noticeably distended [PMID:30138920]. Respiratory problems, including frequent lung infections and difficulty breathing, are also common due to sphingomyelin accumulation in the lungs.
Neurological symptoms are prominent and progressive in NPD-A. Infants may experience developmental delay, losing previously acquired skills (developmental regression). This can include difficulties with movement, muscle weakness (hypotonia), and problems with feeding. Over time, affected children may develop spasticity, meaning stiff and awkward movements, and an inability to coordinate voluntary movements (ataxia). A distinctive cherry-red spot may be observed in the retina during an eye examination in some cases. The progressive nature of these symptoms significantly impacts quality of life.
Video: Genetics 101
Affected organs
Niemann-Pick disease type A impacts multiple organ systems throughout the body. The liver and spleen are almost always enlarged due to the substantial accumulation of sphingomyelin-filled cells. The lungs can also be affected, leading to breathing difficulties and increased susceptibility to respiratory infections.
The central nervous system, including the brain and spinal cord, is severely affected in NPD-A. This leads to the progressive neurological symptoms observed. Bone marrow involvement can contribute to problems with blood cell production. The condition is systemic, meaning it affects virtually all cells and tissues to some degree, but the impact is most pronounced in organs with high metabolic activity or those involved in lipid processing.
Risks & severity
Niemann-Pick disease type A is a severe, rapidly progressive condition. Symptoms usually appear before six months of age, and the disease follows an aggressive course. Life expectancy is significantly reduced, with most children not surviving beyond three years of age due to progressive neurological decline and multi-organ failure [PMID:30138920]. The severity of the disease is generally consistent among individuals diagnosed with NPD-A, reflecting the almost complete absence of functional acid sphingomyelinase enzyme activity. There is currently no cure, and management focuses on supportive care.
Since NPD-A is an inherited condition, individuals with a family history of the disease, particularly if parents are known carriers, have an increased risk. While exact prevalence figures are not well established, it is considered a very rare condition within the general population. There are no known environmental risk factors; genetic inheritance is the sole cause.
Genetic causes
Niemann-Pick disease type A is caused by pathogenic variants in the SMPD1 gene. This gene provides instructions for making an enzyme called acid sphingomyelinase (ASM). ASM is a lysosomal enzyme, meaning it functions within lysosomes, which are membrane-bound compartments inside cells responsible for breaking down waste materials and cellular debris [PMID:33671236].
Normally, ASM breaks down sphingomyelin, a type of fatty substance (lipid), into ceramide and phosphocholine. In individuals with NPD-A, variants in SMPD1 lead to a severe deficiency or complete absence of functional ASM. This prevents the proper breakdown of sphingomyelin, causing it to accumulate within lysosomes. The progressive build-up of sphingomyelin is toxic to cells, impairing their function and eventually leading to cell death and organ damage throughout the body, particularly in the brain, liver, spleen, and lungs [PMID:33671236].
- SMPD1 sphingomyelin phosphodiesterase 1
Inheritance pattern
Niemann-Pick disease type A follows an autosomal recessive pattern of inheritance. This means that a child must inherit two copies of the altered SMPD1 gene - one from each parent - to develop the condition. Individuals who inherit only one altered copy of the SMPD1 gene are called carriers. Carriers typically do not show any symptoms of the disease themselves because they have one working copy of the gene that can produce enough functional acid sphingomyelinase [PMID:30138920].
If both parents are carriers of a pathogenic SMPD1 variant, there is a 25% (1 in 4) chance with each pregnancy that their child will inherit two altered copies and develop NPD-A. There is also a 50% (2 in 4) chance that their child will be a carrier, and a 25% (1 in 4) chance that their child will inherit two typical copies of the gene and will not be a carrier or have the condition. Genetic counselling can provide detailed information and support for families concerned about autosomal recessive inheritance patterns.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
The diagnosis of Niemann-Pick disease type A typically begins with clinical suspicion based on the characteristic symptoms observed in an infant, such as an enlarged liver and spleen, developmental delay, and failure to thrive. Biochemical testing can measure the activity of the acid sphingomyelinase (ASM) enzyme, usually in white blood cells. Very low or absent ASM activity is highly indicative of NPD-A [PMID:30138920].
Confirmation of the diagnosis involves genetic testing to identify pathogenic variants in the SMPD1 gene. This can be performed using DNA extracted from a blood sample. In the UK, genetic testing for Niemann-Pick disease type A may be requested by a specialist clinician, such as a paediatrician or a metabolic specialist, and is typically coordinated through NHS Genomic Medicine Service (GMS) pathways. The relevant NHS National Genomic Test Directory R-code for lysosomal storage disorders, including Niemann-Pick types A/B, would typically be R76. Referrals to clinical genetics services are often made to facilitate testing and provide comprehensive genetic counselling.
Management & lifestyle
Currently, there is no specific cure for Niemann-Pick disease type A, and management is primarily supportive, aimed at alleviating symptoms and improving the child's quality of life. This may involve nutritional support to address feeding difficulties and failure to thrive, respiratory support for breathing problems, and physical and occupational therapy to manage motor challenges. Regular monitoring by a team of specialists, including paediatricians, neurologists, gastroenterologists, and geneticists, is crucial.
Families will typically access care through their local NHS trusts, with specialist input from tertiary centres. Genetic counselling is an important part of the management pathway, providing information about the disease, inheritance patterns, and support services available. While research into new therapies, such as enzyme replacement therapy or gene therapy, is ongoing for some lysosomal storage disorders, these are not yet standard treatments for NPD-A. Clinical trials may be an option for some individuals, where available.
UK care pathway
In the UK, individuals suspected of having Niemann-Pick disease type A would typically be referred by their GP or another specialist to a paediatrician or a metabolic specialist. If a genetic condition is suspected, they would then be referred to a clinical genetics service. These services are part of the NHS Genomic Medicine Service (GMS), which coordinates access to genomic testing and expert advice.
Diagnostic genomic testing for Niemann-Pick disease type A (and related types) is available through the NHS National Genomic Test Directory under specific R-codes, such as R76 for lysosomal storage disorders. Genetic counsellors within these services play a vital role in explaining the genetic basis of the condition, inheritance patterns, and implications for the wider family. They also provide emotional support and help families navigate the complex care pathway.
Frequently asked questions
What is the life expectancy for someone with Niemann-Pick disease type A?
Niemann-Pick disease type A is a very severe condition. Sadly, most children diagnosed with NPD-A do not survive beyond three years of age due to progressive neurological decline and organ failure.
Is there a cure for Niemann-Pick disease type A?
Currently, there is no cure for Niemann-Pick disease type A. Treatment focuses on supportive care to manage symptoms and improve the child's comfort and quality of life.
How is Niemann-Pick disease type A inherited?
Niemann-Pick disease type A is inherited in an autosomal recessive pattern. This means a child needs to inherit a faulty copy of the SMPD1 gene from both parents to develop the condition. Parents who carry one faulty copy typically do not show symptoms themselves.
Can Niemann-Pick disease type A be diagnosed before birth?
Yes, if there is a known family history of Niemann-Pick disease type A and the specific genetic variants in the parents are identified, prenatal diagnosis through chorionic villus sampling or amniocentesis may be possible. This can be discussed with a genetic counsellor.
What is the difference between Niemann-Pick disease type A and type B?
Both types A and B are caused by variants in the SMPD1 gene. However, type A is much more severe, with onset in early infancy and significant neurological problems, while type B typically has a later onset and does not involve severe neurological symptoms, though other organs are affected.
References
- Henry B, Ziobro R, Becker KA. Acid sphingomyelinase. Handbook of experimental pharmacology. 2013. PMID: 23579450
- Kolodny EH. Niemann-Pick disease. Current opinion in hematology. 2000. PMID: 10608504
- Ong WY, Herr DR, Farooqui T. Role of sphingomyelinases in neurological disorders. Expert opinion on therapeutic targets. 2015. PMID: 26243307
- Silvin A, Ginhoux F. Fat-fated microglial dysfunction. The EMBO journal. 2019. PMID: 30567721
- Camoletto PG, Vara H, Morando L. Synaptic vesicle docking: sphingosine regulates syntaxin1 interaction with Munc18. PloS one. 2009. PMID: 19390577
- Audi A, Soudani N, Dbaibo G. Depletion of Host and Viral Sphingomyelin Impairs Influenza Virus Infection. Frontiers in microbiology. 2020. PMID: 32425895
- Breiden B, Sandhoff K. Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease. International journal of molecular sciences. 2020. PMID: 32272755
- Ledesma MD, Prinetti A, Sonnino S. Brain pathology in Niemann Pick disease type A: insights from the acid sphingomyelinase knockout mice. Journal of neurochemistry. 2011. PMID: 21214563